Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02285504 · ClinicalTrials.gov registry record · Phase 2
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02285504 is a Phase 2 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 4 participants.
The verdict
NCT02285504, a Phase 2 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
Interventions
- DRUG SAGE-547
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-01-07 |
| Est. Completion | 2015-06-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02285504
The ClinicalTrials.gov registry entry for NCT02285504 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAGE-547 is the first listed.
NCT02285504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02285504 about?
NCT02285504 is a clinical study titled "Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression". This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
What is the current status of trial NCT02285504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-01-07. Estimated completion is 2015-06-05.
What interventions are being tested in trial NCT02285504?
The interventions under investigation include: SAGE-547 (DRUG).
Who is sponsoring clinical trial NCT02285504?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.